Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $42.33

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fourteen analysts that are presently covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $42.33.

KROS has been the topic of a number of analyst reports. Wedbush lowered Keros Therapeutics from an "outperform" rating to a "neutral" rating and dropped their target price for the stock from $47.00 to $15.00 in a research report on Friday, January 17th. Cantor Fitzgerald downgraded shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Tuesday, January 21st. Oppenheimer decreased their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a research report on Thursday, January 16th. HC Wainwright lowered their price target on Keros Therapeutics from $47.00 to $40.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Finally, William Blair cut shares of Keros Therapeutics from an "outperform" rating to a "market perform" rating in a report on Thursday, December 12th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company's stock worth $42,146,000 after purchasing an additional 46,041 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Keros Therapeutics by 14.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company's stock worth $15,105,000 after acquiring an additional 32,492 shares during the period. SG Americas Securities LLC acquired a new position in Keros Therapeutics during the 4th quarter worth $388,000. Barclays PLC boosted its position in Keros Therapeutics by 140.1% during the 3rd quarter. Barclays PLC now owns 60,014 shares of the company's stock worth $3,484,000 after acquiring an additional 35,022 shares during the period. Finally, Intech Investment Management LLC acquired a new position in Keros Therapeutics during the 3rd quarter worth $603,000. Institutional investors own 71.56% of the company's stock.

Remove Ads

Keros Therapeutics Stock Up 2.5 %

Shares of NASDAQ KROS traded up $0.29 on Monday, hitting $11.96. The company had a trading volume of 246,622 shares, compared to its average volume of 1,550,800. Keros Therapeutics has a 12-month low of $9.77 and a 12-month high of $72.37. The business has a 50 day moving average of $12.20 and a two-hundred day moving average of $38.82. The firm has a market capitalization of $485.20 million, a P/E ratio of -2.29 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, topping analysts' consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $3.04 million for the quarter, compared to analysts' expectations of $37.32 million. On average, sell-side analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.